Market cap
--
Recently Viewed
Clear All$0.02
$0.00
(-0.45%)
As on 28-Nov-2025 09:30EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
--
ROE
--
ROCE
--
Industry P/E
--
EV/EBITDA
--
Debt to Equity
--
Book Value
--
EPS
--
Face value
--
Shares outstanding
--
CFO
$-25.27 Mln
EBITDA
$-34.42 Mln
Net Profit
$-35.48 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lixte Biotechnology Holdings Inc. Warrants (LIXTW)
| -24.1 | -84.0 | -89.3 | -21.1 | -36.3 | -54.4 | -- |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
Company
|
2024
|
2023
|
|---|---|---|
|
Lixte Biotechnology Holdings Inc. Warrants (LIXTW)
| -23.7 | -35.6 |
|
BSE Sensex
| 8.1 | 18.7 |
|
BSE Sensex
| 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b... clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. Read more
President, CEO & Chairman of the Board of Directors
Mr. Bastiaan van der Baan M.Sc.
President, CEO & Chairman of the Board of Directors
Mr. Bastiaan van der Baan M.Sc.
Headquarters
Pasadena, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Lixte Biotechnology Holdings Inc Warrants (LIXTW) is $0.02 (NASDAQ) as of 28-Nov-2025 09:30 EDT. Lixte Biotechnology Holdings Inc Warrants (LIXTW) has given a return of -36.27% in the last 3 years.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-0.02
|
0.08
|
|
2023
|
-0.02
|
0.02
|
|
2022
|
-0.02
|
0.02
|
|
2021
|
-0.09
|
0.13
|
|
2020
|
-0.32
|
0.21
|
The 52-week high and low of Lixte Biotechnology Holdings Inc Warrants (LIXTW) are Rs 0.38 and Rs 0.01 as of 02-May-2026.
Lixte Biotechnology Holdings Inc Warrants (LIXTW) has a market capitalisation of $ 39 Mln as on 28-Nov-2025. As per SEBI classification, it is a company.
Before investing in Lixte Biotechnology Holdings Inc Warrants (LIXTW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.